Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 18/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500786 | 0.94 | HSP90AB1 (0.44) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL501022 | 0.92 | ACHE (0.37) | HSP90AA1HSP90AB1 | |
| SCHEMBL501234 | 0.92 | HSP90AB1 (0.42) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL500645 | 0.90 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL500985 | 0.90 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL500970 | 0.89 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL1865793 | 0.88 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL501565 | 0.86 | HSP90AB1 (0.49) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL500689 | 0.86 | HSP90AB1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL500837 | 0.86 | ACHE (0.37) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937094-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-20 | — | — | US | claimed |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | US | claimed |
| EP-2323737-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | claimed |
| US-9539243-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150126499-A1 | Triazole Compounds that Modulate HSP90 Activity | SYNTA PHARMACEUTICALS CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-8937094-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | US | disclosed |
| US-8486932-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120101072-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-04-26 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126499-A1 | Triazole Compounds that Modulate HSP90 Activity | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20120101072-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.